Aptus Capital Advisors LLC Grows Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Aptus Capital Advisors LLC boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 21.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,778 shares of the exchange traded fund’s stock after acquiring an additional 313 shares during the period. Aptus Capital Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $130,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Pathstone Family Office LLC raised its position in SPDR S&P Biotech ETF by 99.3% during the third quarter. Pathstone Family Office LLC now owns 6,221 shares of the exchange traded fund’s stock worth $454,000 after acquiring an additional 3,099 shares during the period. Banque Cantonale Vaudoise raised its position in SPDR S&P Biotech ETF by 6.6% during the third quarter. Banque Cantonale Vaudoise now owns 13,637 shares of the exchange traded fund’s stock worth $995,000 after acquiring an additional 844 shares during the period. Sumitomo Mitsui Financial Group Inc. raised its position in SPDR S&P Biotech ETF by 10.3% during the third quarter. Sumitomo Mitsui Financial Group Inc. now owns 23,462 shares of the exchange traded fund’s stock worth $1,713,000 after acquiring an additional 2,195 shares during the period. Western Wealth Management LLC acquired a new position in SPDR S&P Biotech ETF during the third quarter worth $201,000. Finally, Kestra Private Wealth Services LLC raised its position in SPDR S&P Biotech ETF by 14.4% during the third quarter. Kestra Private Wealth Services LLC now owns 4,554 shares of the exchange traded fund’s stock worth $333,000 after acquiring an additional 574 shares during the period.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA:XBI opened at $93.17 on Tuesday. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $94.32. The stock has a market capitalization of $7.15 billion, a PE ratio of 11.47 and a beta of 0.97. The company has a fifty day moving average of $87.63 and a two-hundred day moving average of $79.00.

About SPDR S&P Biotech ETF

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Stories

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.